Helix BioPharma (TSE:HBP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix BioPharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor from Laevoroc Immunology AG, enhancing its immune-oncology portfolio. This transaction will involve issuing 16.5% of Helix’s shares to acquire intellectual property and assets, pending regulatory approval. The move aims to expand Helix’s pipeline with promising therapeutic candidates for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.